key: cord-0986491-bzq1d0jf
authors: Lillie, Patrick J; O’Brien, Paul; Lawtie, Michelle; Jessop, Steve; Easom, Nicholas J W; Patmore, Russell
title: First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection
date: 2021-04-24
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab351
sha: b4c85ba92a43c8f5d94f8f179522c9dd9c9825e0
doc_id: 986491
cord_uid: bzq1d0jf

Over the first 2 months of 2021 vaccination coverage of staff at Hull Teaching Hospitals withBNT162b2 increased from 8.3% to 82.5%, and was associated with a significant reduction in symptomatic and asymptomatic SARS-CoV-2 cases. The proportion of positive lateral flow tests from asymptomatic screening was maintained over this period.

The roll-out of vaccination against SARS-CoV-2 in the United Kingdom has included health care workers as a priority group. The efficacy of currently licensed vaccines against symptomatic disease is well documented from clinical trials 1,2 , however there are fewer data with regard to asymptomatic shedding of virus, or the changing pattern of symptoms of those infected as vaccination programs progress. Hull University Teaching Hospitals has used the Pfizer-BioNtech vaccine (BNT 162b2) for staff vaccination, and has been recording testing for SARS-CoV-2 by both Nucleic Acid Amplification Tests (NAAT)for all symptomatic staff and specific screening, together with routine (asymptomatic) Lateral Flow Device (LFD) testing of all clinical staff. Here we present the effect of the vaccine roll out on staff PCR and LFD positivity across symptomatic and asymptomatic groups.

Vaccination with BNT 162b2 began in staff on the 9 th December 2020, with a planned acceleration in staff vaccination from the 28 th December 2020 (figure 1). Vaccination was carried out as per guidelines from Public Health England & the Department of Health 3 . As per guidance from the Joint Committee on Vaccination and Imunisation (JCVI) 3 initial doses have been administered with the booster dose planned for 10 -12 weeks post first vaccination.

Since April 2020, symptomatic staff testing for possible COVID-19 disease has been performed. In addition to testing being triggered by classical symptoms of COVID-19 as per PHE guidance 4 (fever, cough, shortness of breath, loss of smell / taste), we have tested healthcare workers (HCWs) with milder atypical symptoms (nasal symptoms, sore throat, diarrhoea, headache, myalgia / arthralgia) as well as targeted screening during outbreaks and routine screening of staff working on the stem cell transplant unit (116 staff members). Staff contact the hospital testing team and attend within 24 hours for a combined nose and throat swab, which is processed internally by the virology A c c e p t e d M a n u s c r i p t department. A variety of molecular assays are used, with the majority of routine tests being performed using the Panther Fusion (Hologic) assay. Clinical staff in all areas have been performing and electronically self reporting their own LFD tests (Innova) as twice weekly asymptomatic testing since 27 th November 2020. Data on symptomatic / asymptomatic / LFD testing are presented from the week beginning 4 th Jan 2021. We are unable to directly link vaccination status to NAAT or LFD testing amongst staff. All data were collected during routine working practice and no ethical approval was deemed necessary, with the COVID-19 steering group for the trust approving data collection and usage. Statistical testing was performed using GraphPad Prism version 6. showing an initial rate of 332.6 / 100,000 on 9 th Jan 2021 to 144.4 /100,000 on the 19 th Feb 2021 and plateauing from that point. Very few cases of lineage B1.1.7 were present during this period on available whole genome sequencing data, and no other variants of concern were reported.

Health care workers are at high risk of being exposed to SARS-CoV-2 5 and vaccination of this group is a priority. Together with recent data from the SIREN study across UK health care 6 , these data highlight the high level of efficacy of the BNT162b2 vaccine against both symptomatic and asymptomatic infection. We have found that this effect is noted in atypical as well as typical symptoms of COVID-19, hopefully allowing current testing and screening programs to maintain criteria. .

Asymptomatic testing with LFDs has decreased over time, but the proportion of positive tests has remained relatively static, suggesting that sensitivity may be maintained post-vaccination. As the testing by LFD is for routine asymptomatic screening, it is unlikely that the reduction in testing reporting is a direct consequence of the vaccination program, but may reflect both "testing fatigue" or perceived protection from the vaccination. Under reporting, particularly of negative tests is a possible source of bias in this data. In health care settings where positive LFD tests can be confirmed by NAAT testing, these tests may retain utility in a vaccinated group.

Limitations of our data include only short term effectiveness being ascertained, it is an ecological study as opposed to any controlled data and it is data from a single centre in the context of a national vaccine roll out program therefore applicability to other settings is likely to be limited.

A c c e p t e d M a n u s c r i p t

In conclusion single dose BNT162b2 has been associated with a significant decrease in positive PCR for SARS-CoV-2 in both symptomatic and asymptomatic HCW's, with the most dramatic effect on symptomatic illness. Utility of LFD testing positive test rate seems to be unaffected by the vaccine roll out and may continue to provide a useful screening tool in vaccinated cohorts.

Conflict of interest; Dr Easom has received lateral flow test kits from Mologic Ltd for an unrelated project. All other authors have no conflicts of interest. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK

Immunisation against infectious disease

COVID-19: investigation and initial clinical management of possible cases

Pandemic Peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)

M a n u s c r i p t